{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:25:03Z","timestamp":1784373903064,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023B1515020008"],"award-info":[{"award-number":["2023B1515020008"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012457","name":"Basic Research and Frontier Exploration Project of Chongqing","doi-asserted-by":"publisher","award":["2024A04J6485"],"award-info":[{"award-number":["2024A04J6485"]}],"id":[{"id":"10.13039\/501100012457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172713"],"award-info":[{"award-number":["82172713"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.lungcan.2025.108855","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:26Z","timestamp":1764028826000},"page":"108855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Long-term survival with PD-1\/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis"],"prefix":"10.1016","volume":"211","author":[{"given":"Yanna","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108855_b0005","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12890-023-02529-x","article-title":"Rare cavitary lymphoepithelioma-like carcinoma of lung: clinical experience and literature review","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lungcan.2025.108855_b0010","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.2147\/OTT.S241337","article-title":"Pulmonary Lymphoepithelioma-Like Carcinoma: A Mini-Review","volume":"13","author":"Hu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.lungcan.2025.108855_b0015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jso.2930360413","article-title":"Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung","volume":"36","author":"B\u00e9gin","year":"1987","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.lungcan.2025.108855_b0020","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108855_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109937","article-title":"Treatment options for stage III-N2 pulmonary lymphoepithelioma-like carcinoma: A retrospective cohort study","volume":"189","author":"Hou","year":"2023","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2025.108855_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.736940","article-title":"Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma","volume":"8","author":"Fan","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.lungcan.2025.108855_b0035","doi-asserted-by":"crossref","first-page":"453","DOI":"10.21037\/tlcr-23-813","article-title":"Development of a haematological indices-based nomogram for prognostic prediction and immunotherapy response assessment in primary pulmonary lymphoepithelioma-like carcinoma patients","volume":"13","author":"Sheng","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.lungcan.2025.108855_b0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/his.15076","article-title":"Pulmonary squamous cell carcinoma and lymphoepithelial carcinoma\u2009-\u2009morphology, molecular characteristics and differential diagnosis","volume":"84","author":"Berezowska","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2025.108855_b0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00000478-200206000-00004","article-title":"New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas","volume":"26","author":"Chang","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.lungcan.2025.108855_b0050","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1309\/148K-ND54-6NJX-NA61","article-title":"Association of Epstein-Barr virus with lymphoepithelioma-like carcinoma of the lung in southern China","volume":"114","author":"Han","year":"2000","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.lungcan.2025.108855_b0055","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1038\/s41467-019-10902-w","article-title":"The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma","volume":"10","author":"Hong","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2025.108855_b0060","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2334::AID-CNCR6>3.0.CO;2-S","article-title":"Epstein-Barr virus-associated nonsmall cell lung carcinoma: undifferentiated \u201clymphoepithelioma-like\u201d carcinoma as a distinct entity with better prognosis","volume":"82","author":"Chen","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2025.108855_b0065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/030089169508100215","article-title":"Lymphoepithelioma-like carcinoma of the lung. Two cases diagnosed in Caucasian patients","volume":"81","author":"Ferrara","year":"1995","journal-title":"Tumori"},{"key":"10.1016\/j.lungcan.2025.108855_b0070","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/hupa.2001.26457","article-title":"Relationship between Epstein-Barr virus and lymphoepithelioma-like carcinoma of the lung: a clinicopathologic study of 6 cases and review of the literature","volume":"32","author":"Castro","year":"2001","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.lungcan.2025.108855_b0075","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00000478-198908000-00002","article-title":"Lymphoepithelioma-like carcinoma of the lung","volume":"13","author":"Butler","year":"1989","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.lungcan.2025.108855_b0080","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1182\/blood-2014-11-599951","article-title":"The tumor virus landscape of AIDS-related lymphomas","volume":"125","author":"Arvey","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.lungcan.2025.108855_b0085","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3324\/haematol.2018.196725","article-title":"CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth","volume":"104","author":"Casagrande","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.lungcan.2025.108855_b0090","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","article-title":"Defective Epstein-Barr virus in chronic active infection and haematological malignancy","volume":"4","author":"Okuno","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.lungcan.2025.108855_b0095","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.43653","article-title":"CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors","volume":"8","author":"Walens","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.lungcan.2025.108855_b0100","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.lungcan.2025.108855_b0105","article-title":"PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2025.108855_b0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108855_b0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2025.108855_b0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12885-024-13410-3","article-title":"Molecular characterization of EBV-associated primary pulmonary lymphoepithelial carcinoma by multiomics analysis","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2025.108855_b0125","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jtho.2017.10.031","article-title":"Clinical Significance of Plasma Epstein-Barr Virus DNA in Pulmonary Lymphoepithelioma-like Carcinoma (LELC) Patients","volume":"13","author":"Xie","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108855_b0130","article-title":"Association of Epstein-Barr virus (EBV) with lung cancer: meta-analysis","volume":"13","author":"Chen","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2025.108855_b0135","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s41467-022-28479-2","article-title":"EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2025.108855_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107553","article-title":"Expression of PD-L1 in EBV-associated malignancies","volume":"95","author":"Li","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lungcan.2025.108855_b0145","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.lungcan.2015.03.017","article-title":"PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy","volume":"88","author":"Chang","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108855_b0150","doi-asserted-by":"crossref","first-page":"33019","DOI":"10.18632\/oncotarget.5028","article-title":"PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival","volume":"6","author":"Fang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2025.108855_b0155","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41379-019-0391-9","article-title":"A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung","volume":"33","author":"Xie","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2025.108855_b0160","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial","volume":"14","author":"Wu","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108855_b0165","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/nm.3391","article-title":"Tumor metastasis: moving new biological insights into the clinic","volume":"19","author":"Wan","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2025.108855_b0170","doi-asserted-by":"crossref","first-page":"367","DOI":"10.21037\/tlcr.2019.08.16","article-title":"Incidence, prognostic factors, and a nomogram of lung cancer with bone metastasis at initial diagnosis: a population-based study","volume":"8","author":"Zheng","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.lungcan.2025.108855_b0175","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/ijms20040999","article-title":"The Contribution of the Immune System in Bone Metastasis Pathogenesis","volume":"20","author":"Xiang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2025.108855_b0180","first-page":"570","article-title":"The vicious cycle of bone metastases","volume":"2","author":"Guise","year":"2002","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.lungcan.2025.108855_b0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2022.03.006","article-title":"Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays \u201ccold\u201d immune characteristics in Non-small cell lung cancer","volume":"166","author":"Zhu","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108855_b0190","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1111\/1759-7714.13681","article-title":"Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database","volume":"11","author":"Campos-Balea","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.lungcan.2025.108855_b0195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.21037\/atm-20-1471","article-title":"Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases","volume":"9","author":"Qiao","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.lungcan.2025.108855_b0200","doi-asserted-by":"crossref","first-page":"11901","DOI":"10.1038\/s41598-025-91922-z","article-title":"Combination of antiangiogenic and systemic therapy in advanced non-small cell lung cancer: before and after progression to leptomeningeal metastasis","volume":"15","author":"Zhu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2025.108855_b0205","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.21037\/apm-20-1498","article-title":"Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison","volume":"10","author":"Shi","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.lungcan.2025.108855_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1001414","article-title":"Anti-PD-1 antibodies, a novel treatment option for advanced chemoresistant pulmonary lymphoepithelioma carcinoma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2025.108855_b0215","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003191","article-title":"Do the benefits of being a smoker hint at the existence of PD-1\/PD-L1 sensitizers for patients on single-agent immunotherapy?","volume":"9","author":"Zaleskis","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2025.108855_b0220","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/1078-0432.CCR-19-1769","article-title":"Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma","volume":"26","author":"de la Iglesia","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108855_b0225","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40520-021-02025-4","article-title":"Prevalence and clinical outcome of main echocardiographic and hemodynamic heart failure phenotypes in a population of hospitalized patients 70 years old and older","volume":"34","author":"Sonaglioni","year":"2022","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.lungcan.2025.108855_b0230","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.3390\/jcm14082679","article-title":"Clinical Characteristics and Management of Patients Admitted to the Supportive Care Clinic and Predisposing Factors of Unplanned Hospital Readmission: Single-Center Experience","volume":"14","author":"Ba\u015f","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lungcan.2025.108855_b0235","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108855_b0240","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108855_b0245","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108855_b0250","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108855_b0255","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","article-title":"Tislelizumab Versus Docetaxel in Patients WithPreviously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label","volume":"18","author":"Zhou","year":"2023","journal-title":"Randomized Controlled Trial. J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2025.108855_b0260","article-title":"Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2025.108855_b0265","article-title":"Sintilimab plus chemotherapy for first-line treatment of advanced pulmonary lymphoepithelioma-like carcinoma: Phase 2 trial","volume":"6","author":"Lin","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.lungcan.2025.108855_b0270","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jtho.2021.03.016","article-title":"Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis","volume":"16","author":"Liu","year":"2021","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T17:21:35Z","timestamp":1769448095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225007470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":54,"alternative-id":["S0169500225007470"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108855","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term survival with PD-1\/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108855","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108855"}}